Advertisement
YOU ARE HERE: LAT HomeCollectionsJon Fisher
IN THE NEWS

Jon Fisher

FEATURED ARTICLES
CALIFORNIA | LOCAL
April 12, 2008 | James Ricci, Special to The Times
Among naturalists, bird-watchers are odd ducks in that their amateur enthusiasm and participation are warmly welcomed by the scientific professionals in their field. "The study of birds, probably as much as any branch of science, is not only informed by, but almost dependent on, interested amateurs," said Kimball Garrett, ornithology collection manager at the Natural History Museum of Los Angeles County. A case in point is 47-year-old Jon Fisher.
ARTICLES BY DATE
CALIFORNIA | LOCAL
April 12, 2008 | James Ricci, Special to The Times
Among naturalists, bird-watchers are odd ducks in that their amateur enthusiasm and participation are warmly welcomed by the scientific professionals in their field. "The study of birds, probably as much as any branch of science, is not only informed by, but almost dependent on, interested amateurs," said Kimball Garrett, ornithology collection manager at the Natural History Museum of Los Angeles County. A case in point is 47-year-old Jon Fisher.
Advertisement
BUSINESS
July 27, 2005 | From Bloomberg News
Biogen Idec Inc., the company that suspended sales of its Tysabri multiple sclerosis drug in February, said second-quarter profit rose to $34.5 million, lifted by its older multiple sclerosis medicine, Avonex. Net income climbed to 10 cents a share from less than a cent a share, or $827,000, a year earlier when the company had merger-related expenses. Revenue rose 12% to $605.6 million, the Cambridge, Mass.-based company said Tuesday in a statement. Avonex sales jumped 10% to $381.
BUSINESS
August 22, 2003 | From Bloomberg News and Times Staff Reports
Schering-Plough Corp., the maker of Claritin allergy pills and other drugs, said Thursday that it would slash its dividend by 68% to conserve cash as it coped with declining sales and government investigations. The move was another blow to the image of the drug sector on Wall Street, where the stocks had been investor favorites for most of the 1980s and 1990s.
BUSINESS
April 3, 2008 | From Bloomberg News
Best Buy Co. said Wednesday that fourth-quarter profit fell less than analysts estimated on higher sales of more-expensive laptops and video game consoles. The chain forecast that sales and profit this year would rise more than some analysts projected. Shares of Best Buy rose 1.1% on the news. "Apparently the consumer still wants to spend on electronics," said Jon Fisher, a Minneapolis-based portfolio manager at Fifth Third Asset Management.
BUSINESS
January 20, 2005 | From Bloomberg News
Johnson & Johnson said it would return about $11 billion in foreign profit to the U.S., the first company to declare it will take advantage of a one-year tax holiday. The New Brunswick, N.J.-based maker of a variety of products including Band-Aids and heart stents would record a fourth-quarter cost of $800 million in federal and state taxes to bring home the money, it said in a filing with the Securities and Exchange Commission on Wednesday.
SPORTS
October 10, 1987
Monroe 17, Narbonne 13--Defensive back Gary Peterson returned an intercepted pass 10 yards for a touchdown to help Monroe jump out to a 17-0 lead in the first half. Monroe's Kesa Harding scored on a 1-yard quarterback sneak in the first quarter and Jeff Guerra kicked a 22-yard field goal. Narbonne quarterback Shondell Reed hit Eric Williams with a 25-yard touchdown pass with 15 seconds left in the half, giving Narbonne its first score of the season and cutting Monroe's lead to 17-6.
BUSINESS
July 21, 2005 | From Bloomberg News and Times Staff Reports
There may be a lot more smiling faces than usual around Thousand Oaks this week. Shares of Amgen Inc., the biotechnology giant based in that Conejo Valley city, rocketed 15% on Wednesday to an all-time high after the company late Tuesday reported stronger-than-expected second-quarter earnings. The stock soared $10.65 to $81.17, eclipsing the previous peak of $80.43 reached in 2000. The price is up 26.
BUSINESS
February 16, 2002 | THERESA AGOVINO, ASSOCIATED PRESS
Billionaire investor Carl Icahn is seeking antitrust approval to purchase $500 million of ImClone Systems Inc. stock, about 40% of the company. The troubled biotech company announced Friday that Icahn filed documents with the Federal Trade Commission and the Department of Justice to clear the way for him to buy the stock.
BUSINESS
April 7, 2008 | Alana Semuels and Michelle Quinn, Times Staff Writers
In recent months, some start-up technology companies have died or gone into comas after running out of money, a possible early sign that the resurgence in venture investment may be coming to an end. File123 is counting its days. Edgeio was edged out. TripUp has fallen. BrightSpot went dark. Firebrand flamed out and Ezmo is no more. Industry analysts say this year will bring a big wave of start-up deaths as the credit crisis gripping the financial markets makes investors cautious in other areas.
Los Angeles Times Articles
|